BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Meier MA, Calabrese D, Suslov A, Terracciano LM, Heim MH, Wieland S. Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load. J Hepatol 2021:S0168-8278(21)00328-7. [PMID: 34004216 DOI: 10.1016/j.jhep.2021.04.051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Magri A, Harris JM, D’arienzo V, Minisini R, Jühling F, Wing PAC, Rapetti R, Leutner M, Testoni B, Baumert TF, Zoulim F, Balfe P, Pirisi M, Mckeating JA. Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses 2022;14:1070. [DOI: 10.3390/v14051070] [Reference Citation Analysis]
2 Bertoletti A, Boni C. HBV antigens quantity: duration and effect on functional cure. Gut 2021:gutjnl-2021-326258. [PMID: 34799373 DOI: 10.1136/gutjnl-2021-326258] [Reference Citation Analysis]
3 Enomoto M, Umemura T, Suzuki F. I shall be released (from infinite HBV nucleos(t)ide analog therapy): Japanese experience. J Hepatol 2021:S0168-8278(21)01894-8. [PMID: 34245805 DOI: 10.1016/j.jhep.2021.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Karimi-sari H, Rezaee-zavareh MS. Nucleo(s)tide analogue withdrawal in chronic hepatitis B virus infection: Beyond the HBsAg loss. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.04.004] [Reference Citation Analysis]
5 Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci 2021;22:9380. [PMID: 34502289 DOI: 10.3390/ijms22179380] [Reference Citation Analysis]
6 Niklasch M, Zimmermann P, Nassal M. The Hepatitis B Virus Nucleocapsid-Dynamic Compartment for Infectious Virus Production and New Antiviral Target. Biomedicines 2021;9:1577. [PMID: 34829806 DOI: 10.3390/biomedicines9111577] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, Hu J, Wang Y, Tao R, Xiao F, Zhang X, Wang X, Han M, Luo X, Yan W, Ning Q. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol 2022:S0168-8278(22)00066-6. [PMID: 35149125 DOI: 10.1016/j.jhep.2022.01.021] [Reference Citation Analysis]
8 Boettler T, Gill US, Allweiss L, Pollicino T, Tavis JE, Zoulim F. Assessing immunological and virological responses in the liver: implications for the cure of chronic hepatitis B virus infection. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100480] [Reference Citation Analysis]
9 Tsuge M. The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. Liver Int 2021. [PMID: 34559952 DOI: 10.1111/liv.15065] [Reference Citation Analysis]
10 Kostyushev D, Kostyusheva A, Ponomareva N, Brezgin S, Chulanov V. CRISPR/Cas and Hepatitis B Therapy: Technological Advances and Practical Barriers. Nucleic Acid Ther 2021. [PMID: 34797701 DOI: 10.1089/nat.2021.0075] [Reference Citation Analysis]
11 Erken R, Loukachov V, van Dort K, van den Hurk A, Takkenberg RB, de Niet A, Jansen L, Willemse S, Reesink H, Kootstra N. Quantified integrated hepatitis B virus is related to viral activity in patients with chronic hepatitis B. Hepatology 2022. [PMID: 35073596 DOI: 10.1002/hep.32352] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
12 Tu T, Zhang H. Viral integrations in chronic hepatitis B infection: Purposeless passenger or problematic promoter of persistence? Hepatology 2022. [PMID: 35108435 DOI: 10.1002/hep.32388] [Reference Citation Analysis]
13 Loukachov VV, van Dort KA, Erken R, Reesink HW, Kootstra NA. Reply. Hepatology 2022. [PMID: 35318700 DOI: 10.1002/hep.32472] [Reference Citation Analysis]